Good afternoon :)
Inventurus Knowledge Solutions Ltd

Inventurus Knowledge Solutions Ltd

IKS Share Price

NSE
1,868.601.20% (+22.20)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

IKS Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

IKS Performance & Key Metrics

IKS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
42.9317.31
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.016.020.49%

IKS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
88%
Analysts have suggested that investors can buy this stock

from 8 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

IKS Company Profile

Inventurus Knowledge Solutions Limited provides technology-enabled healthcare solutions, focusing on outpatient and inpatient care through its comprehensive care enablement platform.

Investor Presentation

View older View older 

May 13, 2026

PDF
View Older Presentations
PE Ratio
54.37
54.37
1Y Return
13.79%
13.79%
Buy Reco %
75.00
75.00
PE Ratio
81.57
81.57
1Y Return
60.27%
60.27%
Buy Reco %
0.00
0.00
PE Ratio
117.93
117.93
1Y Return
15.37%
15.37%
Buy Reco %
100.00
100.00
PE Ratio
39.43
39.43
1Y Return
1.70%
1.70%
Buy Reco %
0.00
0.00
PE Ratio
41.38
41.38
1Y Return
48.63%
48.63%
Buy Reco %
100.00
100.00
Compare with Peers

IKS Sentiment Analysis

IKS Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

IKS Stock Summary · May 2026

Strong financial performance and materially improved cash conversion set the tone for the call. Q4 revenue of ~INR 857 crore (up ~18.5% YoY) and operating cash flow nearly doubling to INR 863 crore illustrated both growth and liquidity gains, with a Q4 EBITDA margin near 35% and free cash flow covering a large share of PAT. Management emphasized accelerating an AI-native, agentic platform—shipping autonomous workflows, advanced scribing variants and human-in-the-loop designs—while integrating an acqui-hire to advance specialty large-model work and a TruBridge deal to secure longitudinal EHR data for model training. They framed investments in AI, platform consolidation and talent (including rising ESOP costs) as strategic priorities, while acknowledging practical autonomy limits in healthcare, modest pricing pressure on commoditizable features, slower-than-planned cross-sell cadence and a phased COBOL-to-PostgreSQL migration likely to take 18–24 months. They declined to give quarterly guidance, reiterated an FY27 effective tax rate for core operations (~22%), and said the long-term ambition to triple EBITDA to ~INR 3,000 crore and drive net debt toward zero depends on execution of these initiatives.

IKS Stock Growth Drivers
IKS Stock Growth Drivers
9
  • AI-native product progress and market traction

    The company has materially advanced its AI-native product suite and is seeing early commercial traction:

  • Proprietary, explainable AI architecture and capabilities

    Management is building a differentiated AI foundation focused on proprietary specialty large models (SLMs) and

IKS Stock Challenges
IKS Stock Challenges
6
  • Ambient AI scribing adoption and quality shortfalls

    Adoption of the company's ambient AI scribing has plateaued at roughly 50–60% of patient encounters,

  • Limits to automation from clinical edge cases and external counterparties

    Management acknowledged persistent healthcare edge cases that cause generative AI to hallucinate or err, meaning

IKS Forecast

IKS Forecasts

Price

Revenue

Earnings

IKS

IKS

Income

Balance Sheet

Cash Flow

IKS Income Statement

IKS Income Statement

Loading...

Quarterdec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026
Total Revenue573.05634.59643.67647.95684.15727.22743.21784.75820.50862.53
Operating & Other expensessubtract404.83494.15467.11453.70475.70497.78502.34510.75535.74562.84
Depreciation/Amortizationsubtract18.9827.3828.2528.3327.7628.3327.9030.1432.0534.06
Interest & Other Itemssubtract25.5632.2025.9822.2320.5421.0218.0816.1523.3412.68
Taxes & Other Itemssubtract22.1517.3026.8630.7030.4832.2943.3446.9946.0546.99
EPS6.143.845.756.807.808.889.0710.8110.9612.31

IKS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

May 13PDF
Apr 24PDF
Apr 23PDF
+5 more
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 15PDF
Feb 5PDF
 

IKS Stock Peers

IKS Past Performance & Peer Comparison

IKS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHealth Care Equipment & Supplies

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Inventurus Knowledge Solutions Ltd42.9317.31
Poly Medicure Ltd54.376.330.20%
Fischer Medical Ventures Ltd81.577.491.26%
Tarsons Products Ltd117.932.68

IKS Stock Price Comparison

Compare IKS with any stock or ETF
Compare IKS with any stock or ETF
IKS
Loading...

IKS Holdings

IKS Shareholdings

IKS Promoter Holdings Trend

IKS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

IKS Institutional Holdings Trend

IKS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

IKS Shareholding Pattern

IKS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding63.72%2.92%4.58%8.00%20.78%

Sep 2025

Dec 2025

Mar 2026

Jun 2026

IKS Shareholding History

IKS Shareholding History

MarJunSepDec '25MarJun5.39%6.50%7.02%7.56%8.19%8.00%

Mutual Funds Invested in IKS

Mutual Funds Invested in IKS

No mutual funds holding trends are available

Top 5 Mutual Funds holding Inventurus Knowledge Solutions Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.4683%0.53%0.06%94/149 (+2)
0.3525%1.66%0.79%55/99 (+15)
0.2383%0.59%0.11%54/81 (0)

Compare 3-month MF holding change on Screener

IKS Insider Trades & Bulk Stock Deals

IKS Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing IKS stock

smallcases containing IKS stock

Looks like this stock is not in any smallcase yet.

IKS Events

IKS Events

IKS Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

IKS Dividend Trend

No dividend trend available

IKS Dividends

IKS Dividends

Hmm, looks like data is unavailable here. Please come back after some time

IKS Stock News & Opinions

IKS Stock News & Opinions

Corporate
Corporate
Inventurus Knowledge Solutions announces board meeting date

Inventurus Knowledge Solutions will hold a meeting of the Board of Directors of the Company on 5 August 2026.

6 days agoCapital Market - Live
Corporate
Corporate
IKS Health completes acquisition of TruBridge', Inc.

IKS Health announced the successful completion of its previously announced acquisition of TruBridge', Inc. TruBridge is a prominent provider of healthcare technology including an electronic health record (EHR) and revenue cycle management solutions for rural and community hospitals. Following the closing, TruBridge operates as a wholly owned subsidiary of IKS Health. With nearly one in five Americans facing challenges accessing care, rural and community hospitals are under immediate pressure to alleviate administrative, clinical, and operational burdens. To address these systemic challenges, IKS Health is developing a purpose-built, intelligent healthcare operating system designed to optimize the entire care journey. The combined organization supports more than 2,000 healthcare organizations and over 150,000 clinicians across the U.S. Customers of all sizes can expect continued, uninterrupted support, and expanded investment in future innovation. Existing products will remain available as standalone offerings to ensure complete continuity of service. By driving financially sustainable, high-quality, and accountable care across the acute and ambulatory continuum, this scalable technology will deliver transformative value across the entire combined client base, regardless of EHR infrastructure. This acquisition represents a pivotal investment in the rural and community health sector, positioning IKS Health to capture a significant share of a $260 billion total addressable market. By accelerating the deployment of advanced AI capabilities, including specialized large language model (LLM) solutions, IKS Health will enable customers to automate complex workflows and unlock greater value from their clinical data. The transaction is structured to drive long-term shareholder value by broadening customer reach, deepening cross-sell opportunities, and creating a highly scalable business primed for sustainable, profitable growth.

3 weeks agoCapital Market - Live
Corporate
Corporate
Inventurus Knowledge Solutions grants 1.31 lakh stock options

Inventurus Knowledge Solutions has approved the grant of 131,114 stock option to certain eligible employees under the IKS ESOP Plan on 16 June 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Volumes soar at Inventurus Knowledge Solutions Ltd counter

Axis Bank Ltd, Alkyl Amines Chemicals Ltd, J B Chemicals & Pharmaceuticals Ltd, Uno Minda Ltd are among the other stocks to see a surge in volumes on BSE today, 14 May 2026.Inventurus Knowledge Solutions Ltd clocked volume of 1.9 lakh shares by 10:47 IST on BSE, a 14.87 times surge over two-week average daily volume of 12786 shares. The stock gained 0.73% to Rs.1,688.95. Volumes stood at 5835 shares in the last session.Axis Bank Ltd recorded volume of 65.1 lakh shares by 10:47 IST on BSE, a 11.98 times surge over two-week average daily volume of 5.43 lakh shares. The stock lost 1.14% to Rs.1,241.40. Volumes stood at 4.41 lakh shares in the last session.Alkyl Amines Chemicals Ltd witnessed volume of 1.15 lakh shares by 10:47 IST on BSE, a 11.89 times surge over two-week average daily volume of 9684 shares. The stock increased 12.52% to Rs.1,838.15. Volumes stood at 3539 shares in the last session.J B Chemicals & Pharmaceuticals Ltd witnessed volume of 1.56 lakh shares by 10:47 IST on BSE, a 9.35 times surge over two-week average daily volume of 16715 shares. The stock increased 0.77% to Rs.2,111.00. Volumes stood at 14362 shares in the last session.Uno Minda Ltd saw volume of 2.34 lakh shares by 10:47 IST on BSE, a 6.42 fold spurt over two-week average daily volume of 36380 shares. The stock dropped 1.31% to Rs.1,111.40. Volumes stood at 56905 shares in the last session.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Earnings
Inventurus Knowledge Solutions consolidated net profit rises 39.36% in the March 2026 quarter

Net profit of Inventurus Knowledge Solutions rose 39.36% to Rs 205.97 crore in the quarter ended March 2026 as against Rs 147.80 crore during the previous quarter ended March 2025. Sales rose 18.47% to Rs 857.65 crore in the quarter ended March 2026 as against Rs 723.96 crore during the previous quarter ended March 2025. For the full year,net profit rose 48.45% to Rs 721.55 crore in the year ended March 2026 as against Rs 486.06 crore during the previous year ended March 2025. Sales rose 19.89% to Rs 3193.79 crore in the year ended March 2026 as against Rs 2663.99 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales857.65723.96 18 3193.792663.99 20 OPM %34.3831.24 -33.8828.89 - PBDT287.01208.42 38 1029.07718.95 43 PBT252.96180.09 40 904.92606.28 49 NP205.97147.80 39 721.55486.06 48 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Corporate
Inventurus Knowledge Solutions to announce Quarterly Result

Inventurus Knowledge Solutions will hold a meeting of the Board of Directors of the Company on 13 May 2026.

2 months agoCapital Market - Live
Spotlight
Spotlight
Inventurus Knowledge Solutions gains on acquiring TruBridge for $565 million

TruBridge is a fully integrated clinical and financial partner for small and mid-small size hospitals in the USA, offering electronic medical records (EMR) solutions and revenue cycle management (RCM) services. This proposed strategic acquisition underscores a commitment to broaden access to high-quality care and support the clinicians and hospitals that serve communities across the United States. The combined company would bring together IKS Health's care enablement services and TruBridge's expertise in revenue cycle management and electronic health record solutions, particularly for rural and community hospitals. Its goal is to strengthen local healthcare systems and improve access to essential care closer to patients' homes while supporting both ambulatory and acute care. After the merger, the company will focus on improving workflows and operations by combining artificial intelligence with human oversight to address complex challenges. As it integrates more clinical and financial data, the platform is expected to become more efficient and effective, helping healthcare organizations maintain financial stability and focus on patient care. Overall, the organization will provide revenue cycle management, predictive analytics, and advanced EHR solutions to over 2,000 healthcare organizations and more than 150,000 clinicians to improve clinical, operational, and financial performance. Under the terms of the agreement, TruBridge shareholders will receive $26.25 in cash for each share of common stock. The acquisition has been approved by the Boards of Directors of IKS Health, IKS, and TruBridge, and is expected to close during the third calendar quarter of 2026, subject to the satisfaction of customary closing conditions. IKS will finance the acquisition primarily through the incurrence of new indebtedness, including a term loan underwritten by Citibank, JPMorganChase, and Deutsche Bank, which is subject to satisfaction of customary conditions (including approval of the shareholders of IKS Health). Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings. The company's consolidated net profit jumped 41.37% to Rs 183.32 crore on 24.01% jump in revenue from operations to Rs 814.95 crore in Q3 FY26 over Q3 FY25.

3 months agoCapital Market - Live
Corporate
Corporate
IKS announces acquisition of Nasdaq-listed TruBridge Inc.

Inventurus Knowledge Solutions, Inc. (IKS), the U.S. subsidiary of Inventurus Knowledge Solutions (IKS Health), announced it has entered into a definitive agreement to acquire TruBridge, Inc. (NASDAQ: TBRG) (TruBridge), a prominent provider of healthcare technology solutions for rural and community hospitals. This proposed strategic acquisition underscores a commitment to broaden access to high-quality care and support the clinicians and hospitals that serve communities across the United States. By bringing together IKS Health's comprehensive care enablement capabilities that serve a range of healthcare organizations with TruBridge's deep expertise in supporting rural and community hospitals through revenue cycle management and electronic health record (EHR) solutions, the combined healthcare technology company is expected to strengthen local healthcare systems, and enable patients to receive essential care closer to home while also enhancing care delivery across the ambulatory and acute care continuum. Post closing, the combined company will deliver continuous improvement and connected workflows to the core of rural healthcare and to medical groups overall, combining agentic artificial intelligence (AI) with human-in-the-loop expertise to proactively address complex operational challenges. As the platform incorporates a broader range of clinical and financial data, it is designed to become increasingly intelligent and efficient. This growing intelligence, reinforced by human insight, is anticipated to ensure community hospitals and medical groups have the financial resilience and advanced support needed to focus on the health of their patients.

3 months agoCapital Market - Live
Corporate
Corporate
Inventurus Knowledge Solutions grants 75,000 stock options

Inventurus Knowledge Solutions has approved grant of 75,000 employee stock options under the IKS ESOP Plan on 20 February 2026. Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Spotlight
Inventurus Knowledge rallies after Q3 PAT climbs 41% YoY to Rs 183 cr

Profit before tax (PBT) climbed 43.22% YoY to Rs 229.37 crore in Q3 FY26. EBITDA jumped 40% to Rs 281.6 crore in Q3 FY26, registering the growth of 40% compared with Rs 271.8 crore in Q3 FY25.EBITDA margin improved to 34.6% in Q3 FY26 as against 30.5% in Q3 FY25. Sachin K. Gupta, founder & Global CEO, IKS Health,said, 'Our strong Q3 performance, characterized by 24% revenue growth, validatesthat our Care Enablement Platform is the critical solution for a US healthcare market facing a perfect storm of cost, quality, and access pressures. As physician marginsface renewed compression from stagnant reimbursement rates, we are seeing this act as a powerful catalyst for increased outsourcing and platform adoption. We continue to deepen our value proposition by advancing our AI capabilities'specifically moving our Patient Engagement suite toward multi-agent orchestration'to drive cognitive reasoning and independent action. Our recent wins with partners like StrideCare and VitalMD demonstrate that provider enterprises are increasingly choosing our integrated platform to ensure their financial sustainability and clinical efficiency.' Nithya Balasubramanian, Group CFO, IKS Health said, 'Our Q3 FY2026 performance underscores our consistent ability to drive profitable growth and deliver significant value to our clients. We achieved a 24% year-on-year revenue increase and a 41% growth in Profit After Tax (PAT), fueled by continuous expansion across existing and new client relationships. Margin expansion is a direct result of our successful operating leverage, technology deployment and focused cost management. ' Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings.Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Inventurus Knowledge Solutions Ltd (IKS) today?

    The share price of IKS as on 4th August 2026 is ₹1868.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Inventurus Knowledge Solutions Ltd (IKS) share?

    The past returns of Inventurus Knowledge Solutions Ltd (IKS) share are
    • Past 1 week: 3.64%
    • Past 1 month: -0.46%
    • Past 3 months: 11.59%
    • Past 6 months: 12.72%
    • Past 1 year: 17.65%
    • Past 3 years: N/A%
    • Past 5 years: -5.84%

  3. What are the peers or stocks similar to Inventurus Knowledge Solutions Ltd (IKS)?
  4. What is the market cap of Inventurus Knowledge Solutions Ltd (IKS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Inventurus Knowledge Solutions Ltd (IKS) is ₹30974.74 Cr as of 4th August 2026.

  5. What is the 52 week high and low of Inventurus Knowledge Solutions Ltd (IKS) share?

    The 52-week high of Inventurus Knowledge Solutions Ltd (IKS) is ₹1933 and the 52-week low is ₹1262.

  6. What is the PE and PB ratio of Inventurus Knowledge Solutions Ltd (IKS) stock?

    The P/E (price-to-earnings) ratio of Inventurus Knowledge Solutions Ltd (IKS) is 42.93. The P/B (price-to-book) ratio is 17.31.

  7. Which sector does Inventurus Knowledge Solutions Ltd (IKS) belong to?

    Inventurus Knowledge Solutions Ltd (IKS) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.

  8. How to buy Inventurus Knowledge Solutions Ltd (IKS) shares?

    You can directly buy Inventurus Knowledge Solutions Ltd (IKS) shares on Tickertape. Simply sign up, connect your demat account and place your order.